Halozyme Therapeutics Inc (HALO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $112.45 (+2.53%), Market cap $7.58B, P/E ratio 24.98, 52-week low–high $47.91 ~ $81.23.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED,
Financial statements, price targets, institutional (13F) holdings and related news for Halozyme Therapeutics Inc are updated in real time on BlackAll Trade.
Halozyme Therapeutics Inc trades at $112.45 (+2.53%). Real-time quotes and charts are available on BlackAll Trade.
Halozyme Therapeutics Inc has a market cap of about $7.58B. Its P/E ratio is 24.98.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internation